An Aging-Related lncRNA Signature Establishing for Breast Cancer Prognosis and Immunotherapy Responsiveness Prediction
Yanshijing Zhou,Zihui Yang,Hong Zeng
DOI: https://doi.org/10.2147/pgpm.s450960
2024-05-24
Pharmacogenomics and Personalized Medicine
Abstract:Yanshijing Zhou, 1 Zihui Yang, 2 Hong Zeng 2 1 Department of Plastic and Cosmetic Surgery, Maternal and Child Health Hospital of Hubei Province, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Department of Plastic and Cosmetic Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China Correspondence: Zihui Yang; Hong Zeng, Department of Plastic and Cosmetic Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China, Email ; Purpose: Emerging evidence demonstrates the vital role of aging and long non-coding RNAs (lncRNAs) in breast cancer (BC) progression. Our study intended to develop a prognostic risk model based on aging-related lncRNAs (AG-lncs) to foresee BC patients' outcomes. Patients and Methods: 307 aging-related genes (AGs) were sequenced from the TCGA project. Then, 697 AG-lncs were identified by the co-expression analysis with AGs. Using multivariate and univariate Cox regression analysis, and LASSO, 6 AG-lncs, including al136531.1, mapt-as1, al451085.2, otud6b-as1, tnfrsf14-as1 , and linc01871 , were validated to compute the risk score and establish a risk signature. Expression levels of al136531.1, mapt-as1, al451085.2, tnfrsf14-as1 , and linc01871 were higher in low-risk BC patients, whereas otud6b-as1 expression was higher in high-risk BC patients. In the training and testing set, high-risk patients performed shorter PFI, OS, and DFS than low-risk patients. Results: Our risk signature had the highest concordance index among other established prognostic signatures and displayed ideal predictive ability for 1-, 3- and 5-year patient OS in the nomogram. Additionally, BC patients with different risk score levels showed different immune statuses and responses to immunotherapy via GSEA, ssGSEA, ESTIMATE algorithm, and TIDE algorithm analysis. Of note, the qRT-PCR analysis validated that these 6 AG-lncs expressed quite differentially in BC tissues at various clinical stages. Conclusion: The risk signature of 6 AG-lncs might offer a novel prognostic biomarker and promisingly enhance BC immunotherapy's effectiveness. Keywords: risk model, senescence, immune, cancer therapy Globally, the number of newly diagnosed cases (11.7%) of female breast cancer (BC) is about 2.3 million, surpassing lung cancer as the most prevalent malignancy. 1 BC possesses metastatic heterogeneity and plasticity, with varying colonization preferences in distinct organs, such as brain, lung, liver, and bone. 2 Although there are tremendous advances in therapeutic strategy, given the highly invasive characteristic, it continues to be confronted with undesirable prognoses during recent decades. 3 Therefore, the efforts to screen prognostic indicators and build accurate models for anticipating the prognosis are still critical for BC control. With the update and advancements in genome sequencing technology, various newly emerging molecules have been screened out as significant participants in BC that were not previously appreciated. 4 Tumor evolution commonly results in abnormally regulated epigenetic events, such as aberrant non-coding RNA (ncRNA) expression levels and DNA methylation. These altered ncRNAs in BC cells can accurately or partially reflect the information originating from primary and metastatic sites. 5 Thus, it poses the potential prognostic implications of ncRNAs in BC outcomes. For instance, circ_0069094 was upregulated in paclitaxel‐resistant BC tissues and cells, involving in tumor growth and invasion through competitively sponging miR-136-5p . 6 Pathogenesis and progression of malignant breast tumors have been linked to long noncoding RNAs (lncRNAs). LncRNAs function as key molecular mechanisms to regulate genomic activity, acting as tumor suppressors or oncogenes. 7 LncRNAs can not be translated into proteins, but directly mediate gene modification, transcription, and translation, performing as competitive endogenous RNAs. 8 In addition, lncRNAs are involved in multiple signaling pathways, which modify tumor immunity, cellular metabolism, cellular proliferation, and angiogenesis. LncRNAs extensively participate in the oncogenesis and progression of BC. For instance, BC lung metastasis dormancy was induced by the modulation of NR2F1 and Np63 by lncRNA nr2f1-as1 , underlining the importance of this regulator in BC stem-like cell plasticity and metastatic dormancy. 9 In addition, lncRNA SNHG1 could facilitate the capabilities of proliferation, migration, in -Abstract Truncated-
pharmacology & pharmacy